Taxotere (Docetaxel) New Indication: Squamous Cell Carcinoma of the Head and Neck (SCCHN) Treatment Registration Trial
Status:
Completed
Trial end date:
2018-01-26
Target enrollment:
Participant gender:
Summary
The Primary Objective is to evaluate the progression-free survival after treatment with
docetaxel plus cisplatin plus 5-Fluorouracil (5-FU) (DCF) in comparison with cisplatin plus
5-FU (CF) in patient with locally advanced inoperable SCCHN The Secondary Objective is to
evaluate and compare the clinical response rate both before and after radiotherapy, the local
symptoms, the duration of response, the time to treatment failure, the survival, the toxicity
and the quality of life in the 2 study groups.